Grade A
Rct
Featured
Rapamycin and Cellular Senescence: Phase 2 Clinical Trial
Phase 2 RCT examining low-dose rapamycin effects on senescent cell markers, immune function, and biological aging in healthy older adults.
Published 2024
23 views
[STUDY DETAILS]
- Study Type
- Rct
- Quality Grade
- A
- Publication Year
- 2024
- Category
- Longevity & Aging
Summary
12-month RCT (n=150) found weekly low-dose rapamycin (1mg) reduced p16INK4a expression by 22%, improved vaccine response by 38%, and decreased IL-6 by 15% in adults 65-80.
Key Findings
1. Senescence marker p16 reduced 22%
2. Vaccine response improved 38%
3. IL-6 inflammation -15%
4. Mild GI effects resolved by month 3